VOLABIOS focuses on detecting schizophrenia early and monitoring it over time. The project begins on 1 January 2025. Its consortium gathers 18 partners and two affiliated entities from 11 European countries, with expertise in academia, clinical research, technology, public health and policy-making. Firalis is one of the partners.
The project studies volatile organic compounds (VOCs) released by the body. Measured by mobile spectrometry, they offer a non-invasive route to biomarkers of the disease, and artificial intelligence is used to analyse the resulting data. An advisory committee of experts in psychiatry and neuroscience guides the work.
Research phases
- a retrospective analysis of 9 million medical records, 120,000 of them linked to schizophrenia;
- clinical research with 3,692 patients from six medical centres in Europe, followed for 18 to 36 months;
- a blind study with 1,000 participants to validate the biomarkers.
The role of Firalis
Firalis takes part in the validation of the VOC biomarkers and brings its biobank to the project, for the secure, standardised storage of samples collected at clinical sites across Europe. The biobank works under ISO 9001, ISO 20387 and ISO 14001: see Biobank & clinical studies.
Source Firalis SA press release, Huningue, December 2024.
